These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35464416)

  • 21. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
    Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
    Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
    Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
    Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
    Lim CH; Koh YW; Hyun SH; Lee SJ
    Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
    Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
    J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Programmed Death Receptor Ligand One Expression May Independently Predict Survival in Patients With Non-Small Cell Lung Carcinoma Brain Metastases Receiving Immunotherapy.
    Hulsbergen AFC; Mammi M; Nagtegaal SHJ; Lak AM; Kavouridis V; Smith TR; Iorgulescu JB; Mekary RA; Verhoeff JJC; Broekman MLD; Phillips JG
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):258-267. PubMed ID: 32335185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Biopsy Study.
    Xie W; Jiang Z; Zhou X; Zhang X; Zhang M; Liu R; Zheng L; Xin F; Lu Y; Wang D
    Acad Radiol; 2023 Jul; 30(7):1317-1328. PubMed ID: 36369191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
    Saad MB; Hong L; Aminu M; Vokes NI; Chen P; Salehjahromi M; Qin K; Sujit SJ; Lu X; Young E; Al-Tashi Q; Qureshi R; Wu CC; Carter BW; Lin SH; Lee PP; Gandhi S; Chang JY; Li R; Gensheimer MF; Wakelee HA; Neal JW; Lee HS; Cheng C; Velcheti V; Lou Y; Petranovic M; Rinsurongkawong W; Le X; Rinsurongkawong V; Spelman A; Elamin YY; Negrao MV; Skoulidis F; Gay CM; Cascone T; Antonoff MB; Sepesi B; Lewis J; Wistuba II; Hazle JD; Chung C; Jaffray D; Gibbons DL; Vaporciyan A; Lee JJ; Heymach JV; Zhang J; Wu J
    Lancet Digit Health; 2023 Jul; 5(7):e404-e420. PubMed ID: 37268451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
    Yoon J; Suh YJ; Han K; Cho H; Lee HJ; Hur J; Choi BW
    Thorac Cancer; 2020 Apr; 11(4):993-1004. PubMed ID: 32043309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
    Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
    EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiparameter spectral CT-based radiomics in predicting the expression of programmed death ligand 1 in non-small-cell lung cancer.
    Zheng XX; Ma YQ; Cui YQ; Dong SS; Chang FX; Zhu DL; Huang G
    Clin Radiol; 2024 Apr; 79(4):e511-e523. PubMed ID: 38307814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
    Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
    Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
    [No Abstract]   [Full Text] [Related]  

  • 34. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
    Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
    Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy.
    Hashimoto K; Murakami Y; Omura K; Takahashi H; Suzuki R; Yoshioka Y; Oguchi M; Ichinose J; Matsuura Y; Nakao M; Okumura S; Ninomiya H; Nishio M; Mun M
    Clin Lung Cancer; 2024 Jan; 25(1):e26-e34.e6. PubMed ID: 37673781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
    Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
    Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
    Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
    PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
    Jiang M; Sun D; Guo Y; Guo Y; Xiao J; Wang L; Yao X
    Acad Radiol; 2020 Feb; 27(2):171-179. PubMed ID: 31147234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing brain metastasis prediction in non-small cell lung cancer: a deep learning-based segmentation and CT radiomics-based ensemble learning model.
    Gong J; Wang T; Wang Z; Chu X; Hu T; Li M; Peng W; Feng F; Tong T; Gu Y
    Cancer Imaging; 2024 Jan; 24(1):1. PubMed ID: 38167564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.